COVID-19, Russia will test efficacy of its vaccine in more than 40,000 people
Russia announced the start of clinical trials with more than 40,000 people of its COVID-19 vaccine, announced on August 11 and viewed with skepticism by the international community.
"Next week, a clinical study on the efficacy and safety of the Sputnik V vaccine will begin in Russia," indicated the Russian sovereign fund, associated with its development, specifying that more than 40,000 people will participate in the study in more than 45 Medical centers.
The official website dedicated to the vaccine, for its part, had announced that phase 3 of the clinical trials, with more than 2,000 people in various countries, had started on August 12.
The director of the sovereign wealth fund, Kirill Dmitriev, pointed out during an online briefing that the vaccination of risk groups, which includes health personnel, will also begin next week on a voluntary basis.
More than 20 countries have placed purchase orders for 1 billion doses of the vaccine, he added. He also said that Russia has agreed to produce the vaccine in five countries.
Dmitriev also indicated that "mass vaccinations in Russia are planned to begin in October," while deliveries of vaccines abroad are scheduled to begin in November or December. A delegation from the Saudi Arabian Ministry of Health is expected in Moscow next week, he added.
Sputnik V, the name that refers to the first artificial satellite in history, is viewed with skepticism in most of the world, especially due to the lack of a final phase of tests at the time of being announced.
"We have seen a significant change in the tone that the WHO (World Health Organization) uses. At first, in fact, they did not have enough information about the Russian vaccine, now official information has been sent to them and they will evaluate it," he continued. Dmitriev.